Nav: Home

Experimental drug takes aim at cancers associated with Epstein-Barr virus

August 22, 2018

Washington, DC - August 22, 2018 - Epstein-Barr Virus (EBV) doesn't directly cause cancer, but infection with this common herpes virus brings an increased risk of some cancers, including fast-growing lymphomas. This week in mSphere, researchers report on a new drug that works by targeting EBV-positive tumors.

In experiments on mice, the drug inhibited tumor development and metastases for EBV-related lymphomas. The findings suggest the drug may be useful in treating malignancies in EBV-positive patients and have led to a phase I trial in that patient population.

The Epstein-Barr virus is so common that almost everyone in the United States has been infected by the time they reach their twenties. An infection can cause mononucleosis (the "kissing disease"), but many people remain asymptomatic their entire lives. An increased risk of other types of cancer, including nasopharyngeal and stomach cancers, has been associated with EBV infections.

"In certain circumstances the virus can contribute to cancer.," says the study's lead author, microbiologist Richard Longnecker at the Northwestern University Feinberg School of Medicine, in Chicago.

Infections by EBV are thought to promote the growth of B lymphocytes, resulting in lymphomas. Importantly, EBV encodes a protein called LMP2A (Latent Membrane Protein 2A) that can hijack the cell signaling mechanism of the B cells it infects. Longnecker, whose research focuses on understanding how viruses contribute to cancer, has been studying the protein since the late 1980s. His laboratory has found that LMP2A can both prevent apoptosis, or cell death, and drive the cell-division cycle, promoting cancer in murine models.

For the new study, Longnecker and his collaborators studied mice that had been genetically modified to express LMP2A protein in B cells that promoted lymphoma development. In treated mice, the drug, a tyrosine kinase inhibitor called TAK-659, counteracted the cancer-promoting mechanisms of the LMP2A protein. The drug killed tumor cells but left host cells unaffected. It also promoted apoptosis in tumor cells and stopped the spread of tumor cells into nearby bone marrow.

Based on previous preclinical studies conducted at Takeda Pharmaceuticals, which is developing TAK-659, the company launched three phase I clinical trials to test the safety of the drug in patients with some lymphomas, acute myelogenous leukemia, and some solid tumors. Those studies are recruiting. Based on the findings published this week in mSphere, which validated the drug's efficacy in EBV-positive lymphomas, the company added a cohort of EBV-positive patients to one of those trials.

The drug has promise both as a single agent and in combination with other cancer therapies, including immunotherapies, says Karuppiah Kannan, Global Program Leader for Takeda, which is based in Cambridge, Massachusetts. "It combines very well with checkpoint inhibitors," he says. Kannan says the new findings demonstrate the drug's efficacy can be tested not only among different types of cancer, but more generally among those associated with EBV.

The findings published this week, says Kannan, show how good preclinical data can push research faster toward something that will help patients. "It's an example of how bench to bedside happens," he says. "Now the clinical data has to take us to the next step."
-end-
The American Society for Microbiology is the largest single life science society, composed of more than 30,000 scientists and health professionals. ASM's mission is to promote and advance the microbial sciences.

ASM advances the microbial sciences through conferences, publications, certifications and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences.

American Society for Microbiology

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

The Cancer-Fighting Kitchen, Second Edition: Nourishing, Big-Flavor Recipes for Cancer Treatment and Recovery
by Rebecca Katz (Author), Mat Edelson (Author)

The Emperor of All Maladies: A Biography of Cancer
by Siddhartha Mukherjee (Author)

F*ck Cancer: A totally inappropriate self-affirming adult coloring book (Totally Inappropriate Series) (Volume 4)
by Jen Meyers (Author)

Anticancer: A New Way of Life
by David Servan-Schreiber MD PhD (Author)

The Truth about Cancer: What You Need to Know about Cancer's History, Treatment, and Prevention
by Ty M. Bollinger (Author)

Chris Beat Cancer: A Comprehensive Plan for Healing Naturally
by Chris Wark (Author)

How to Starve Cancer
by Jane McLelland (Author)

Left Boob Gone Rogue: My Life With Breast Cancer
by Uzma Yunus MD (Author)

The Metabolic Approach to Cancer: Integrating Deep Nutrition, the Ketogenic Diet, and Nontoxic Bio-Individualized Therapies
by Dr. Nasha Winters ND FABNO L.Ac Dipl.OM (Author), Jess Higgins Kelley MNT (Author), Kelly Turner (Foreword)

The Biology of Cancer, 2nd Edition
by Robert A. Weinberg (Author)

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#514 Arctic Energy (Rebroadcast)
This week we're looking at how alternative energy works in the arctic. We speak to Louie Azzolini and Linda Todd from the Arctic Energy Alliance, a non-profit helping communities reduce their energy usage and transition to more affordable and sustainable forms of energy. And the lessons they're learning along the way can help those of us further south.